Rapid Fire Live Tumor Board™: Leveraging Clinical Data on CAR T to Inform Treatment Decision Making Across Heme Malignancies

Release Date: June 11, 2021
Expiration Date: June 30, 2022

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in chimeric antigen receptor (CAR T)-cell therapy to discuss a series of case presentations that will offer tightly integrated clinical trial data to highlight treatment decisions related to patient and disease characteristics. In this educational activity, these experts will also discuss the management of adverse events in a variety of settings.

This educational activity is an archive of the live virtual webcast held on June 4, 2021.

Acknowledgement of Commercial Support

This activity is supported by educational grants from bluebird bio, Inc., Kite Pharma, Inc., Legend Biotech USA, Inc., and Novartis Pharmaceuticals Corporation.

Target Audience

This educational program is directed toward the ASCO audience, including hematologists and medical oncologists interested in the treatment of hematologic malignancies. Other allied health care professionals, including pathologists, nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with hematologic malignancies will also be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Describe the mechanism of action and unique properties of CAR T cells as living therapeutics
• Evaluate the efficacy and safety profiles of CAR T-cell therapies evaluated for the treatment of hematological malignancies
• Implement proactive multidisciplinary strategies to identify and minimize the impact of CAR T-cell–related toxicities in patients with hematological tumors
• Apply evidence from landmark trials evaluating CAR T-cell therapies in hematological malignancies to real-world case scenarios in the management of patients with these diseases

Faculty Disclosures

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible entities.

Chair

Disclosures: Grant/Research Support: to University of Miami: Allogene, Atara, Autolus, Bristol Myers Squibb, Iovance, Janssen, Kite, Novartis; Consultant:, Atara, Autolus, Bristol Myers Squibb, Incyte, Iovance, Janssen, Kiadis, Kite/Gilead, Novartis, Takeda, UnitedHealth.

Faculty

Disclosures: Grant/Research Support: Kite Pharma, Novartis Pharmaceuticals Corporation; Consultant: Arcellx, Bristol Myers Squibb, Iovance Biotherapeutics, Kite Pharma, Novartis Pharmaceuticals Corporation.

Disclosures: Partow Kebriaei, MD, has no relevant financial relationships with ineligible companies.

Disclosures: Grant/Research Support: Allogene Therapeutics, Janssen Pharmaceuticals (research funding to institution), Magenta Therapeutics; Consultant: Janssen Pharmaceuticals.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.